These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 11816832)

  • 1. RWJ-333441 Microcide/RW Johnson.
    Jiraskova N
    Curr Opin Investig Drugs; 2001 Feb; 2(2):209-11. PubMed ID: 11816832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prodrugs of cephalosporin RWJ-333441 (MC-04,546) with improved aqueous solubility.
    Hecker SJ; Calkins T; Price ME; Huie K; Chen S; Glinka TW; Dudley MN
    Antimicrob Agents Chemother; 2003 Jun; 47(6):2043-6. PubMed ID: 12760896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Water-soluble phosphate prodrugs of pleuromutilin analogues with potent in vivo antibacterial activity against Gram-positive pathogens.
    Fu L; Jiang Z; Cai Z; Liu X; He H; Yang Y
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5407-10. PubMed ID: 19682897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MC-207110 Daiichi Seiyaku/Microcide Pharmaceuticals.
    Barrett JF
    Curr Opin Investig Drugs; 2001 Feb; 2(2):212-5. PubMed ID: 11816833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of cefpodoxime, an oral 3rd generation cephalosporin.
    Raymond N; Lang S
    N Z Med J; 1993 Feb; 106(949):44. PubMed ID: 8464593
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro evaluation of Ly 163892, a new oral cephalosporin.
    Schäfer V; Knothe H; Sammann A; Heidron F
    J Chemother; 1989 Jul; 1(4 Suppl):123-4. PubMed ID: 16312333
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.
    Parish D; Scheinfeld N
    Curr Opin Investig Drugs; 2008 Feb; 9(2):201-9. PubMed ID: 18246523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
    Morrissey I; Ge Y; Janes R
    Int J Antimicrob Agents; 2009 Jun; 33(6):515-9. PubMed ID: 19203863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel cephalosporin derivatives possessing a substituted cinnamoyl moiety at the 7 beta-position. Synthesis, structural characterization and antibacterial activity of 3-acetoxymethyl cephalosporin derivatives.
    López MA; Rodríguez Z; González M; Tolón B; Avila R; González I; Garmendía L; Mamposo T; Carrasco R; Pellón R; Vélez H; Fini A
    Eur J Med Chem; 2004 Aug; 39(8):657-64. PubMed ID: 15276299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-spectrum beta-lactamases: the end of cephalosporins?
    Colodner R; Raz R
    Isr Med Assoc J; 2005 May; 7(5):336-8. PubMed ID: 15909470
    [No Abstract]   [Full Text] [Related]  

  • 12. New broad-spectrum parenteral cephalosporins exhibiting potent activity against both methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Part 2: Synthesis and structure-activity relationships in the S-3578 series.
    Yoshizawa H; Kubota T; Itani H; Ishitobi H; Miwa H; Nishitani Y
    Bioorg Med Chem; 2004 Aug; 12(15):4211-9. PubMed ID: 15246097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prodrug approach toward the development of water soluble fluoroquinolones and structure--activity relationships of quinoline-3-carboxylic acids.
    Baker WR; Cai S; Dimitroff M; Fang L; Huh KK; Ryckman DR; Shang X; Shawar RM; Therrien JH
    J Med Chem; 2004 Sep; 47(19):4693-709. PubMed ID: 15341485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of potential prodrugs of RWJ-445167, an oxyguanidine-based dual inhibitor of thrombin and factor Xa.
    Maryanoff BE; McComsey DF; Costanzo MJ; Yabut SC; Lu T; Player MR; Giardino EC; Damiano BP
    Chem Biol Drug Des; 2006 Jul; 68(1):29-36. PubMed ID: 16923023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cephalosporin resistance among animal-associated Enterobacteria: a current perspective.
    Batchelor M; Threlfall EJ; Liebana E
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):403-17. PubMed ID: 15954857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New molecules from old classes: revisiting the development of beta-lactams.
    Page MG; Heim J
    IDrugs; 2009 Sep; 12(9):561-5. PubMed ID: 19697275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-MRSA beta-lactams in development.
    Page MG
    Curr Opin Pharmacol; 2006 Oct; 6(5):480-5. PubMed ID: 16899405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.